Erenumab
Stories
-
Amgen posts results of Phase 3 erenumab trial in pediatric chronic migraine
The study, completed with 284 participants, evaluated erenumab in children 6 to <12 years and adolescents 12 to <18 years with chronic migraine. Results were first posted on ClinicalTrials.gov on October 28, 2026.